Protein tyrosine kinases (PTKs) regulate numerous signal transduction pathways, including those controlling cell growth, differentiation, and the activation of lymphocytes and platelets (5, 53, 58) . In each instance, signal transduction is triggered by stimulation of a cell surface receptor which either has kinase activity itself or is physically and/or functionally linked to an intracellular PTK. Recent evidence suggests that the integrins, cell surface receptors for proteins of the extracellular matrix (ECM), are also transducers of cytoplasmic signals (19, 20, 52) , and activation of this pathway is linked to one or more PTKs (15, 25) . A candidate PTK for a mediator of integrin signalling is focal adhesion kinase (pp125FAK), a PTK that colocalizes with integrins to sites of cell-ECM contact (16, 48) . Tyrosine phosphorylation of ppl25FAK is stimulated by engagement of the integrins with their ligands (reviewed in references 20, 50, and 60) .
A recurring theme that has emerged from the study of PTKs is that tyrosine phosphorylation of the kinase itself plays an important part in regulating its functional activities. The phosphorylation of PTKs on tyrosine can occur by autophosphorylation, through either an intramolecular or an intermolecular mechanism (e.g., receptor PTKs), or PTKs can serve as substrates for other PTKs (for example, pp6oc-src and related Src family kinases which are phosphorylated by C-terminal Src kinase [8, 38] ). Tyrosine phosphorylation can serve to inhibit the catalytic activity of these enzymes, as in the case of pp6Qsrc (reviewed in reference 8), to enhance enzymatic activity, e.g., the insulin and Met/HGF receptors (39, 47, 59) , and to create high-affinity binding sites for proteins that contain Src homology 2 (SH2) domains (51, 56) . SH2 domains mediate proteinprotein interactions by binding to a phosphotyrosine-contain-ing sequence motif (43, 44) . The specificity of such binding is dictated by the residues flanking the site of tyrosine phosphorylation as well as the structural characteristics of a particular SH2 domain (12, 54) . Examples drawn from growth factor receptor PTK signalling illustrate the importance of SH2-phosphotyrosine interactions in the transmission of cytoplasmic signals. For example, receptor PTK autophosphorylation can recruit SH2-containing substrates to the receptor complex, thereby facilitating their phosphorylation. In turn, the phosphorylation of certain substrates appears to be critical for the regulation of their activities (for example, the growth factordependent activation of phospholipase C&y [13, 23, 40] ). SH2-phosphotyrosine interactions also provide a mechanism by which cytosolic enzymes whose substrates are present in cell membranes can be translocated to the proximity of their substrates (for example, phospholipase C&y and phosphatidylinositol 3-kinase, cytosolic enzymes whose substrates are membrane lipids [9, 26, 37] , and Sos, a cytosolic protein that functions as a guanine nucleotide exchange factor for the membrane-associate protein p2lras [34] ). Binding of a tyrosinephosphorylated protein to an SH2 domain-containing enzyme can lead directly to an increase in enzymatic activity. For example, binding of a tyrosine-phosphorylated peptide to the SH2 domain of the regulatory 85-kDa subunit of phosphatidylinositol 3-kinase (P13K) induces conformational changes in p85 and the concomitant increase in enzymatic activity of the holoenzyme (2, 6, 35, 41) . Finally, SH2-phosphotyrosine interactions may be critical for the negative regulation of enzymatic activity. For example, c-Src kinase activity is regulated by the binding of its SH2 domain to the C-terminal regulatory site of tyrosine phosphorylation, Tyr-527 (5, 8) . Thus, phosphotyrosine-SH2 interactions not only mediate protein-protein complex formation but are also intimately involved in the regulation of the activity of a number of signalling molecules.
The PTK pp125FAK is phosphorylated on tyrosine in response to the engagement of cell surface integrins with com-ponents of the ECM (4, 14, 16, 24, 29, 49) , and concomitantly, its enzymatic activity, measured in vitro, is elevated (14, 29 (17, 18, 49) . The resulting plasmids were transfected into CE cells as described previously (46) . Protein analysis. Cells were lysed in modified radioimmunoprecipitation assay buffer (21) , and protein concentrations determined by a bicinchoninic acid protein assay (Pierce). Immune complexes were prepared from 0.5 to 1 mg of cell lysate, using rabbit anti-pp125FAK serum (BC3) (48) or the monoclonal antibody (MAb) 2A7 (22) . pp6Q"rc immune complexes were prepared by using MAb EC10 (42) . The complexes were collected by using protein A-Sepharose beads (Pharmacia). For complexes formed with MAbs the beads were preincubated with affinity-purified rabbit anti-mouse immunoglobulin G (Jackson ImmunoResearch). The immune complexes were washed twice with modified radioimmunoprecipitation assay buffer and twice with Tris-buffered saline (10 mM Tris-HCl [pH 8.0], 150 mM NaCl). Total cell lysate or immune complexes were denatured in Laemmli sample buffer and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (27) . Western blotting (immunoblotting) with pp125F' antiserum or affinity-purified rabbit antiphosphotyrosine antibodies has been described elsewhere (22) . In some experiments, enhanced chemiluminescence (Amersham) was used as the detection system for Western blotting.
Kinase assays and peptide mapping. ppl25FAK-containing immune complexes were prepared as outlined above and washed once with kinase reaction buffer [20 mM piperazine- N,N'-bis(2-ethanesulfonic acid (PIPES; pH 7.2), 3 mM MnClj2. ppl25FAK was autophosphorylated by incubation in kinase reaction buffer containing 10 to 20 pLCi of [-y-32P]ATP (6, 000 Ci/mmol; NEN) for 20 min at room temperature (48) .
The reaction was terminated with the addition of sample buffer, and the labelled proteins were analyzed by SDS-PAGE and autoradiography. Phosphorylation of an exogenous substrate, poly(Glu,Tyr) (4:1; Sigma), was carried out as described above except that the reaction mixture also contained 0.4 ,ug of poly(Glu,Tyr) and 5 ,uM unlabelled ATP. The reaction was terminated by addition of ice-cold EDTA to a final concentration of 0.25 M, and the pp125FAK-containing immune complexes were removed by centrifugation. Poly(Glu,Tyr) was precipitated from the supernatant with trichloroacetic acid, and the incorporation of 32p was monitored by liquid scintillation counting. The amount of FAK in each immune complex was determined by Western blotting with BC3 and detected with 125I-protein A (NEN). The amount of 1251 bound was determined by excising each band and counting in an LKB 1272 Clinigamma automated gamma counter. 3 P incorporation into poly(Glu,Tyr) was then normalized to reflect differences in the amount of pp125FAK present in the immune complexes.
The synthetic peptide VSVSETDDYAEIIDEED (Quality Controlled Biochemicals) was phosphorylated in vitro, using ppFAK-containing immune complexes. The reaction was terminated by addition of ice-cold EDTA (as described above), and the peptide was separated from [y-32P]ATP by highvoltage electrophoresis and thin-layer chromatography (TLC) as described below. The 32P-peptide was recovered and digested with thermolysin, and the phosphopeptides were analyzed as described below.
For peptide mapping, 32P-labelled pp125FAK was electrophoretically transferred to a nitrocellulose membrane or was excised from the gel, eluted, and collected by precipitation with trichloroacetic acid. Radiolabelled pp125F K was then digested with trypsin, chymotrypsin, thermolysin, or V8 protease as described previously (3, 31) . Phosphopeptides were resolved by high-voltage electrophoresis (30 min at 1,000 V in pH 1.9 buffer [3] for tryptic peptides; 20 min at 1,300 V in pH 4.72 buffer for other peptides) followed by chromatography in isobutyric acid buffer (3). Positions of phosphorylated peptides were determined by autoradiography. Individual phosphopeptides were isolated by aspiration onto a polyethylene disk (Omnifit) followed by elution in 1.9 buffer (3).
In vivo labelling. CE cells overexpressing pp125FAK were incubated in phosphate-free Dulbecco modified Eagle medium containing 2 mCi of 32p; (8, 500 to 9,120 Ci/mmol; NEN) per ml supplemented with 10% (vol/vol) conditioned medium for 8 to 10 h at 37°C. Cells were lysed, and labelled ppl25FAK was immunoprecipitated and subjected to phosphopeptide analysis as outlined above.
Peptide sequencing. 32P-labelled phosphotryptic peptides were scraped from TLC plates and eluted as described above. The peptide was applied to Sequelon acrylamine membrane (Milligen), dried, and coupled (10) . After four washes with 9% trifluoroacetic acid-27% acetonitrile (55), the membranebound peptide was placed into an Applied Biosystems 470A sequencer. The sequencing cycles used 90% methanol-1 mM phosphate (pH 7.0) for extraction of derivatized amino acids from the membrane as described previously (1, 55) . The products of each cleavage reaction were collected, and 32p was detected by Cerenkov counting.
Site-directed mutagenesis. The FAK cDNA was subcloned into the pALTER-1 mutagenesis vector (Promega). Selected tyrosine codons were mutated to phenylalanine codons by oligonucleotide-directed mutagenesis, and mutants were iden-VOL. 14, 1994 on tified by nucleotide sequence analysis of individual cDNA clones. Appropriate cDNAs were subcloned into RCAS for expression in CE cells (17) .
RESULTS
Phosphopeptide mapping of ppl25FAK. Autophosphorylation of PTKs is an important initiating event in signal transduction; thus, we sought to identify the site(s) of autophosphorylation of pp125 pp125FA becomes phosphorylated exclusively on tyrosine in an in vitro immune complex protein kinase assay (data not shown). Phosphopeptide maps of ppl25FAK autophosphorylated in vitro were established by using either trypsin or chymotrypsin. Each enzyme yielded four phosphopeptides, one major and three less prominent peptides ( Fig. 1A and B) . The intensities of the latter varied from experiment to experiment. Digestion with V8 protease yielded two major phosphopeptides (Fig. 1C) , and digestion with thermolysin revealed a single major phosphopeptide (Fig. 1D) . Identical tryptic phosphopeptides were obtained from in vitrophosphorylated recombinant pp125FAK immunoprecipitated from Escherichia coli extracts, which contain no endogenous PTKs, indicating that phosphorylation of ppi25FAK in immune complexes is the result of autophosphorylation, as opposed to transphosphorylation by a copurifying PTK (data not shown). The relative simplicity of each of the peptide maps indicated phosphorylation of a limited number of tyrosine residues in vitro. Furthermore, when each individual tryptic phosphopeptide (Fig. 1A ) was isolated and subjected to further digestion with V8 (or thermolysin), the tryptic peptides yielded identical maps (data not shown). These results clearly indicated that each of these labelled phosphopeptides harbored the same phosphorylated tyrosine residue. An identical conclusion was reached upon secondary digestion of individual chymotryptic phosphopeptides with V8 or thermolysin (data not shown).
To establish whether the same tyrosine residues were phosphorylated in vivo and in vitro, the phosphopeptide maps of pp125FAK phosphorylated in vitro in an immune complex kinase reaction were compared with phosphopeptide maps of ppl25F immunoprecipitated from cells radiolabelled in vivo with 32p (Fig. 2) . In vivo-labelled ppl25FAK yielded a more complex pattern of phosphopeptides; however, a subset of these peptides were identical to the peptides generated from ppl25FAK labelled in vitro. Both the tryptic phosphopeptides Ti and T2 and the chymotryptic phosphopeptides Cl, C2, C3, and C4 were evident in the maps of pp125FAK labelled in vivo ( Fig. 2A and D ) and in vitro ( Fig. 2B and E) . Mixing experiments confirmed that the phosphopeptides labelled in vitro comigrated with the corresponding phosphopeptides from the in vivo-labelled pp125FAK (Fig. 2C and F) . Phosphoamino acid analysis of phosphopeptides Ti, T2, Cl, C2, C3, and C4 from the in vivo-labelled material revealed predominantly phosphotyrosine (data not shown). A small amount of phosphoserine was also detected, the significance of which is presently unclear. The phosphopeptide mapping data described above demonstrate that the major site of tyrosine phosphorylation of pp125FAK in vivo corresponds to a site that becomes phosphorylated when ppl25FAK undergoes autophosphorylation in an immune complex kinase reaction in vitro.
Identification tide maps of dl51-377 and d1686-1011 were virtually identical to the maps of wild-type pp125FAK ( Fig. 3 and data not shown), indicating that the site of autophosphorylation of ppl25FAK resides between residues 377 and 686 (Fig. 3) . The region between amino acids 377 and 686 comprises the catalytic domain and short regions of flanking sequence and contains 12 candidate sites for tyrosine phosphorylation. Therefore, direct sequence analysis of the major tryptic phosphopeptide, Ti, was carried out to identify putative autophosphorylation sites. Ti was isolated and sequenced by automated Edman degradation, and the position of the labelled phosphotyrosine was determined by monitoring each sequencing cycle for the release of 32p. As illustrated in Fig. 4, 32p was recovered in the 12th cycle, indicating that the phosphorylated tyrosine was 12 residues to the C-terminal side of an arginine or lysine. Three tyrosines, Tyr-397, Tyr-526, and Tyr-652, were thus identified as candidate sites of tyrosine phosphorylation (Fig.   4 ).
ppl25FAK autophosphorylation on Tyr-397. A genetic strategy was applied to distinguish which of these tyrosine residues was the major site of autophosphorylation. Tyr-397, Tyr-526, and Tyr-652 were individually mutated to phenylalanine by site-directed mutagenesis. In addition, another mutant was created in which phenylalanines were substituted for both Tyr-526 and Tyr-528. Analysis of this latter mutant precludes the possibility that elimination of a major autophosphorylation site at residue 526 would result in autophosphorylation of a cryptic site residing a few residues away, which would in turn obscure the loss of the phosphorylation site at 526. Each mutant was recloned into the retroviral vector RCAS and expressed in CE cells. Analysis of CE cells expressing the Tyr-526, Tyr-526/528, and Tyr-652 mutants (pmY526F, pmY526/528F, and pmY652F) showed that each variant exhibited wild-type levels of tyrosine phosphorylation and wild-type autophosphorylating activity in vitro, and each was phosphorylated on the same site as the wild-type protein, as determined by phosphotryptic and phosphochymotryptic peptide analysis (data not shown). In contrast, FAK397F (the protein encoded by the mutant pmY397F) exhibited no significant phosphorylation on tyrosine when expressed in CE cells (Fig. SA) and exhibited significantly reduced autophosphorylating activity in an in vitro immune complex kinase assay (Fig. SB) . The autophosphorylation deficiency did not result from the mutation ablating enzymatic activity, since FAK397F displayed approximately 50% of the wild-type level of enzymatic activity when assayed with poly(Glu,Tyr) as an exogenous substrate (Fig. 6) . Furthermore, expression of pmY397F in E. coli as a glutathione S-transferase fusion protein induced the tyrosine phosphorylation of E. coli proteins, as judged by Western blotting with antiphosphotyrosine antibodies (data not shown). Finally, phosphotryptic peptide maps of FAK397F, labelled by autophosphorylation in vitro, lacked phosphopeptides Ti through T4. However, small amounts of a novel phosphotryptic peptide were observed, presumably reflecting autophosphorylation at a cryptic site due to the loss of Tyr-397 (data not shown).
To confirm that Tyr-397 is the major site of autophosphorylation, a peptide (VSVSETDDYAEIIDEED) identical in sequence to the region surrounding Tyr-397 was synthesized and phosphorylated in vitro, using pp125FAK. The (Fig. 7) . Thus, both the genetic and biochemical evidence support the conclusion that the major autophosphorylation site of ppI25FAK is Tyr-397.
FAK397F fails to stably associate with pp6t'rc. (Fig. 8) . Wild-type pp125FAK was readily detected in the Src immune complexes from cells expressing both FAK and Src (Fig. 8B) ; however, FAK397F was not detected in Src immune complexes from doubly infected cells expressing both pmY397F and Src (Fig. 8B) . These results provide evidence that autophosphorylation of pp125FAK creates a high-affinity binding site for pp6W7rf and leads to the stable association of Src and FAK in vivo.
DISCUSSION
The phosphorylation of PTKs on tyrosine residues is a critical regulatory event that modulates catalytic activity (39, 47, 59) and triggers the physical association of PTKs with SH2-containing proteins (43, 44, 51) . The integrin-linked PTK, pp125FAK, exhibits ECM-dependent phosphorylation on tyrosine (4, 14, 16, 24, 29, 49) Fig. 1 . A mixture of the two samples is shown in panel C.
ppl25FAK (36) . Whereas phosphorylation of these residues in vivo is dependent on platelet-derived growth factor stimulation, it has not been established whether they are truly sites of autophosphorylation. It is clear however, that one of these sites functions as a binding site for the SH2 domain of pp6Qsrc (36) . Thus, the binding of pp6Qsrc to phosphorylated tyrosine residues to the N-terminal side of the catalytic domains of other PTKs is a feature of several PTKs.
The interaction of ppl25FAK with SH2 domains in vitro and SH2-containing proteins in vivo appears to be highly specific. In vitro, pp125FK can bind to the Src and Fyn SH2 domains but binds poorly to a variety of others, including the SH2 domains from phospholipase C-y and SHC (7) . Selective binding to SH2-containing proteins also appears to take place in vivo. In cells transformed by v-Src or v-Crk, pp6Qsrc and pp47gag-crk, each of which contains an SH2 domain, bind to numerous tyrosine-phosphorylated proteins via their SH2 domains (32, 33, 45) . However, pp125FAK, which is tyrosine phosphorylated in both Src-and Crk-transformed cells, binds poorly to pp47crk and extremely well to pp6Q"rc (2a, 7) . Given the foregoing observations, it was not surprising to find that the sequences flanking the autophosphorylation site of ppl25FAK conform to a near-optimal binding site for the SH2 domain of pp6Orc. The autophosphorylation site of pp125FAK, Y397 AEI, is very similar to the consensus of a high-affinity Src SH2-binding peptide, YEEI (54) . Interestingly, the FAK autophosphorylation site differs from the tyrosine-phosphorylated sequence present in the juxtamembrane region of the PDGF-R. These latter sites do not resemble the canonical Src SH2-binding sequence (36) . It is noteworthy that the threedimensional structural analysis of Src family SH2 domains complexed to high-affinity binding peptides revealed that the most important features stabilizing the interaction were the phosphorylated tyrosine residue and the isoleucine lying three residues to the C-terminal side (11, 57) . It is interesting to speculate that in addition to mediating the formation of complexes between pp125FAK and pp6osrc, autophosphorylation at Tyr-397 might create a high-affinity binding site for other unidentified, SH2-containing, ppl25FAK-binding proteins. In addition, other minor sites of tyrosine phosphorylation which differ in primary sequence from the Tyr-397 site may create binding sites for SH2-containing proteins that recognize different sequence motifs (for example, the sequence Y-923VPM... may function as a binding site for the phosphatidylinositol 3-kinase). A complete understanding of the role of autophosphorylation in regulating the association of proteins with pp125FAK awaits future analysis. pp125FAK becomes tyrosine phosphorylated when fibroblasts adhere to ECM proteins and upon the activation of resting platelets (4, 14, 16, 24, 29, 49) . Concomitantly, ppl25FA becomes enzymatically activated, as measured in an in vitro kinase assay (14, 29) . It has been unclear whether the observed phosphorylation on tyrosine contributes to the enzymatic activation of pp125FAK or merely serves as an indicator of activation in vivo. The variant FAK397F, which is largely devoid of phosphotyrosine, readily catalyzes the phosphorylation of poly(Glu,Tyr) in vitro and induces the phosphorylation of cellular proteins in E. coli. However, FAK397F appears to be somewhat impaired in its catalytic activity since immune complexes containing FAK397F reproducibly catalyze the phosphorylation of poly(Glu,Tyr) at about half the rate of immune complexes containing wild-type FAK. These observations indicate that phosphorylation does not regulate the enzymatic activity of pp125FAK. However, at present we cannot exclude the possibility that phosphorylation plays an essential role in the regulation of ppl25FA when assayed under different conditions or with a different substrate. In addition, we cannot exclude the effects of phosphorylation on other residues styrosine, serine, or threonine) upon the activity of pp125FA
The integrins are fundamentally important biological molecules that operate at both the level of the individual cell, e.g., in adherence and migration, and at the organismal level, e.g., in differentiation and development and in the orchestration of the immune response and blood clotting. One function of the integrins is to transduce an extracellular cue into-a cytoplasmic signal, a function that is presumably important for the biological activities of integrins. We speculate that integrin engagement with the ECM leads to either the direct clustering of pp125FAK, allosteric changes in pp125FAK, or the stimulation of an intermediary molecule which triggers FAK activation. As we have shown here, the activation of ppl25FAK results in autophosphorylation and generation of a high-affinity binding site for Src and Src family kinases. Under normal circumstances, the enzymatic activities of pp6ffrc and pp59)fy are repressed through the action of a negative regulatory element at the C terminus of these kinases (Fig. 9) . Phosphorylation of a highly conserved tyrosine within this region by a regulatory PTK is critical for down-regulation of catalytic activity (8) . In the current model for Src regulation, pp6Qsrc bites its tail; i.e., the tyrosine phosphorylated C-terminal sequence binds in an intramolecular interaction to its own SH2 domain (5, 8) . While a tyrosine-phosphorylated C-terminal peptide can bind to the SH2 domain of pp6Q"rc, the amino acid sequence flanking the tyrosine does not resemble the consensus high-affinity binding site and binds poorly to Src SH2 domains (54) . Indeed, pp6Qsrc can be enzymatically activated in vitro by incubation with a synthetic phosphopeptide containing the consensus Src SH2-binding site, presumably by outcompeting the regulatory C terminus from the SH2 domain (30) . It is therefore intriguing to speculate that autophosphorylation of Tyr-397 of ppl25FA may create a high-affinity binding site for 60rc and pp59Vfl and that these kinases may bind to pp125 A , resulting in the displacement of their C termini from their SH2 domains (Fig.  9) . Thus, binding to pp125FAK may be a mechanism by which pp6Qsrc and pp59y'f are enzymatically activated in addition to a mechanism for the recruitment of these kinases to a highly localized site within the cell.
